1. Home
  2. GOSS vs PEPG Comparison

GOSS vs PEPG Comparison

Compare GOSS & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gossamer Bio Inc.

GOSS

Gossamer Bio Inc.

HOLD

Current Price

$0.39

Market Cap

104.7M

Sector

Health Care

ML Signal

HOLD

Logo PepGen Inc.

PEPG

PepGen Inc.

HOLD

Current Price

$1.65

Market Cap

113.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GOSS
PEPG
Founded
2015
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
104.7M
113.3M
IPO Year
2018
2022

Fundamental Metrics

Financial Performance
Metric
GOSS
PEPG
Price
$0.39
$1.65
Analyst Decision
Buy
Strong Buy
Analyst Count
8
6
Target Price
$4.19
$11.17
AVG Volume (30 Days)
8.7M
2.4M
Earning Date
05-14-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
25.61
EPS
N/A
N/A
Revenue
$48,471,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$201.64
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.32
$1.01
52 Week High
$3.87
$7.80

Technical Indicators

Market Signals
Indicator
GOSS
PEPG
Relative Strength Index (RSI) 37.36 23.13
Support Level $0.33 $1.57
Resistance Level $0.47 $5.37
Average True Range (ATR) 0.04 0.13
MACD 0.04 0.09
Stochastic Oscillator 46.72 26.68

Price Performance

Historical Comparison
GOSS
PEPG

About GOSS Gossamer Bio Inc.

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).

About PEPG PepGen Inc.

PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.

Share on Social Networks: